May 07, 2019 4:20pm EDT OPKO Health Reports 2019 First Quarter Business Highlights and Financial Results
Apr 12, 2019 8:00am EDT OPKO Reports Additional Oxyntomodulin, OPK-88003, Results From Phase 2 Diabetes and Obesity Trial
Mar 21, 2019 8:00am EDT OPKO Announces Positive Topline Results In Phase 2 Diabetes And Obesity Trial
Feb 27, 2019 4:05pm EST OPKO Health Reports 2018 Fourth Quarter Business Highlights and Financial Results
Feb 26, 2019 8:00am EST OPKO Health to Announce Fourth Quarter 2018 Financial Results on February 27, 2019
Feb 05, 2019 8:30am EST OPKO Health, Inc. Announces the Pricing of its Offering of Convertible Senior Notes
Feb 01, 2019 8:00am EST OPKO Health Receives FDA Approval for the Point-of-Care Sangia PSA Test with the Claros® 1 Analyzer